Analyst Research

2024

SP Angel – New in vitro data on STAT-6 programme shows activity in modulating inflammation

6 November 2024

Download (pdf, 439.71 KB)

SP Angel – Initiation of Coverage

5 September 2024

Download (pdf, 1.06 MB)

2023

Hybridan LLP – Significant Mesodermal killer cell therapy milestone

6 November 2023

Download (pdf, 441.91 KB)

Hybridan LLP – RNA oligonucleotide program shows in vitro anti-cancer efficacy

22 June 2023

Download (pdf, 473.82 KB)

Hybridan LLP – Midkine antibody in-vivo efficacy results and pursuit of an orphan drug indication (osteosarcoma)

19 June 2023

Download (pdf, 481.92 KB)

Hybridan LLP – Successful completion of in vitro studies of anti-cancer Midkine mRNA therapeutic

14 June 2023

Download (pdf, 469.03 KB)

Hybridan LLP – Licencing of Midkine IP to Randox

20 February 2023

Download (pdf, 438.8 KB)

2022

Hybridan LLP – Completion of Oncogeni Acquisition

16 September 2022

Download (pdf, 427.24 KB)

Hybridan LLP - Initiation of Coverage

12 September 2022

Download (pdf, 839.92 KB)

Optiva Securities - Research Report

17 May 2022

Download (pdf, 1.83 MB)

Pitt Street - Evaluation Report

10 January 2022

Download (pdf, 658.36 KB)